BeOne Medicines (BEIGF) Gross Profit Growth (1y) (2018 - 2026)
Analysis
BeOne Medicines (BEIGF) Gross Profit Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn | 7.10% |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn | 14.64% |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn | -0.30% |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn | -2.37% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 0.62% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 23.11% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn | 38.03% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | -3.83% |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 33.01% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.01% |
| Mar 31, 2026 | 41.37% |
| Dec 31, 2025 | 40.16% |
| Sep 30, 2025 | 46.28% |
| Jun 30, 2025 | 45.47% |
| Mar 31, 2025 | 51.95% |
| Dec 31, 2024 | 82.99% |
| Sep 30, 2024 | 21.33% |
| Jun 30, 2024 | 58.44% |
| Mar 31, 2024 | 71.23% |
| Dec 31, 2023 | 72.41% |
| Sep 30, 2023 | 120.20% |
| Jun 30, 2023 | 84.64% |
| Mar 31, 2023 | 51.63% |
| Dec 31, 2022 | 85.31% |
| Sep 30, 2022 | 95.62% |
| Jun 30, 2022 | 137.76% |
| Mar 31, 2022 | -57.89% |
| Dec 31, 2021 | 109.35% |
| Sep 30, 2021 | 127.32% |